Difference between revisions of "Dostarlimab (Jemperli)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: PD-1 receptor antibody. <br>Route: IV <br>Extravasation: no information For conciseness and simplicity, HemOnc.org currently will foc...") |
m (→Also known as) |
||
| Line 13: | Line 13: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:'' TSR-042 | + | *'''Code name:''' TSR-042 |
*'''Generic name:''' dostarlimab-gxly | *'''Generic name:''' dostarlimab-gxly | ||
*'''Brand name:''' Jemperli | *'''Brand name:''' Jemperli | ||
Revision as of 13:53, 23 April 2021
General information
Class/mechanism: PD-1 receptor antibody.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 4/22/2021: Granted accelerated approval for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen.
Also known as
- Code name: TSR-042
- Generic name: dostarlimab-gxly
- Brand name: Jemperli